Table 1 Clinical features of the training cohort.
Variables | Control cohort (n = 209) | NVCFs cohort (n = 31) | p |
|---|---|---|---|
Sex, n (%) | 0.544 | ||
Male | 42.0 (20.2%) | 5.0 (15.6%) | |
Female | 166.0 (79.8%) | 28 (90.3%) | |
Age (years) | 73.12 ± 10.00 | 77.59 ± 9.49 | 0.018 |
BMI (kg/m2) | 22.80 ± 3.44 | 21.07 ± 3.97 | 0.025 |
BMD | − 2.43 ± 1.25 | − 3.32 ± 1.39 | 0.001 |
History of hypertension, n (%) | 0.105 | ||
Yes | 110.0 (52.9%) | 12.0 (37.5%) | |
No | 98.0 (47.1%) | 20.0 (62.5%) | |
History of diabetes, n (%) | 0.814 | ||
Yes | 36.0 (17.3%) | 5.0 (15.6%) | |
No | 172.0 (82.7%) | 27.0 (84.4%) | |
Augmentation segment, n (%) | 0.011 | ||
T5–7 | 18.0 (8.7%) | 9.0 (28.1%) | |
T8–12 | 146.0 (70.2%) | 18.0 (56.3%) | |
L1–5 | 44.0 (21.2%) | 5.0 (15.6%) | |
Bone cement dosage (ml) | 4.89 ± 1.28 | 4.81 ± 1.29 | 0.756 |
Bone cement leakage, n (%) | 0.079 | ||
Yes | 48.0 (23.1%) | 20.0 (62.5%) | |
No | 160.0 (76.9%) | 12.0 (37.5%) | |
Bone cement dispersion, n (%) | 0.012 | ||
Yes | 203.0 (97.6%) | 27.0 (84.4%) | |
No | 5.0 (2.4%) | 5.0 (15.6%) | |
Bone cement distribution, n (%) | 0.079 | ||
Type I | 16.0 (7.7%) | 2.0 (6.3%) | |
Type II | 45.0 (21.6%) | 4.0 (12.5%) | |
Type III | 111.0 (53.4%) | 14.0 (43.8%) | |
Type VI | 36.0 (17.3%) | 12.0 (37.5%) | |
Contact with the endplates, n (%) | 0.012 | ||
Yes | 7.0 (3.4%) | 5.0 (15.6%) | |
No | 201.0 (96.6%) | 27.0 (84.4%) | |
Anti-osteoporotic treatment, n (%) | 0.004 | ||
Yes | 96.0 (46.2%) | 6.0 (18.8%) | |
No | 112.0 (53.8%) | 26.0 (81.3%) | |
Scoliosis, n (%) | 0.032 | ||
Yes | 64.0 (30.8%) | 16.0 (50.0%) | |
No | 144.0 (69.2%) | 16.0 (50.0%) | |
Pre-op AVH (mm) | 19.74 ± 5.77 | 12.87 ± 5.15 | < 0.001 |
Post-op AVH (mm) | 22.98 ± 4.92 | 17.93 ± 4.84 | < 0.001 |
AVHRR, n(%) | 12.97 ± 13.27 | 24.01 ± 11.19 | < 0.001 |
Pre-op Cobb angle (°) | 6.68 ± 5.88 | 9.61 ± 6.64 | 0.034 |
Post-op Cobb angle (°) | 6.10 ± 5.66 | 9.11 ± 6.03 | 0.018 |
Cobb angle restoration (%) | 31.66 ± 27.78 | 42.56 ± 21.05 | 0.019 |
